GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs

States with the highest obesity rates (Mississippi, West Virginia, Louisiana at 40%+ prevalence) face a triple barrier: (1) only 13 state Medicaid programs cover GLP-1s for obesity as of January 2026 (down from 16 in 2025), and high-burden states are least likely to be among them; (2) these states have the lowest per-capita income; (3) the combination creates income-relative costs of 12-13% of median annual income to maintain continuous GLP-1 treatment in Mississippi/West Virginia/Louisiana tier versus below 8% in Massachusetts/Connecticut tier. Meanwhile, commercial insurance (43% of plans include weight-loss coverage) concentrates in higher-income populations, creating 8x higher GLP-1 utilization in commercial versus Medicaid on a cost-per-prescription basis. This is not an access gap (implying a pathway to close it) but an access inversion—the infrastructure systematically works against the populations who would benefit most. Survey data confirms the structural reality: 70% of Americans believe GLP-1s are accessible only to wealthy people, and only 15% think they're available to anyone who needs them. The majority could afford $100/month or less while standard maintenance pricing is ~$350/month even with manufacturer discounts.

Extending Evidence

Source: KFF Medicaid GLP-1 Coverage Analysis, January 2026

As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obesity under fee-for-service Medicaid, despite nearly 40% of adults and 25% of children with Medicaid having obesity. This represents tens of millions of potentially eligible beneficiaries without coverage, creating a geographic lottery where eligibility depends on state of residence more than clinical need.

Extending Evidence

Source: KFF analysis of Medicare GLP-1 Bridge program (April 2026)

The Medicare GLP-1 Bridge program demonstrates that access inversion operates at the federal program design level, not just state-level coverage decisions. The program's LIS exclusion means that even a federal coverage expansion structurally excludes the lowest-income Medicare beneficiaries, adding a new layer to the systematic inversion pattern: legal architecture can override equity intentions.

Supporting Evidence

Source: KFF 2025 poll condition-specific usage

Among patients with diagnosed conditions showing clear clinical benefit, uptake remains limited: 45% of diabetes patients and 29% of heart disease patients currently using GLP-1s. Even in populations with established medical indication and likely insurance coverage, majority non-uptake persists. The 56% affordability difficulty rate among current users demonstrates cost barriers operate even after initial access is achieved.

Extending Evidence

Source: HR Brew December 2025, 9amHealth partnership announcements

The utilization vs. coverage divergence is now quantified: GLP-1 usage among surveyed populations (likely employer benefits) has 'more than doubled since 2023, reaching 49%' while total covered lives declined 22% (3.6M → 2.8M). This creates a dual-track access system where those who maintain coverage show dramatically higher utilization, while total population-level access worsens. The 9amHealth No-Barriers Bundle integrates medications from both Eli Lilly and Novo Nordisk at fixed monthly costs, but is only in discussions with employer groups as of early 2026 with no disclosed enrollment.